Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics.
The effects of the (+) and (-) enantiometers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), 9,10-didehydro-6-methyl-8 beta-(2-pyridylthiomethyl)ergoline (CF 25-397) and 6,7-dihydroxy-2-dimethyl-aminotetralin (TL 99), three agonists of the postulated presynaptic dopamine receptor, on the pattern of brain glucose metabolism were studied using the autoradiographic technique of Sokoloff et al. [19]. It was found that these drugs modify brain glucose metabolism in a way similar to the neuroleptics but different from postsynaptic agonists. These results support the suggestion that these drugs could represent a new type of neuroleptic.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D002395:Catecholamines / Q000502:physiology; D004873:Ergolines / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism*; D009281:Naphthalenes / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*
D014150:Antipsychotic Agents; D002395:Catecholamines; D004873:Ergolines; D009281:Naphthalenes; D010880:Piperidines; D013764:Tetrahydronaphthalenes; C012145:CF 25397; C016893:2-(N,N-dimethylamino)-6,7-dihydroxytetralin; D012110:Reserpine; C026539:preclamol; D005947:Glucose; D001058:Apomorphine